Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic ar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Brachat, Arndt H., Grom, Alexei A., Wulffraat, Nico, Brunner, Hermine I., Quartier, Pierre, Brik, Riva, McCann, Liza, Ozdogan, Huri, Rutkowska-Sak, Lidia, Schneider, Rayfel, Gerloni, Valeria, Harel, Liora, Terreri, Maria, Houghton, Kristin, Joos, Rik, Kingsbury, Daniel, Lopez-Benitez, Jorge M., Bek, Stephan, Schumacher, Martin, Valentin, Marie-Anne, Gram, Hermann, Abrams, Ken, Martini, Alberto, Lovell, Daniel J., Nirmala, Nanguneri R., Ruperto, Nicolino
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5260050/
https://ncbi.nlm.nih.gov/pubmed/28115015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1212-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados